文献速递银屑病与炎症性皮肤病

口服利特昔替尼治疗活动性非节段性白癜风的有效性与安全性:一项随机2b期临床试验

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
PubMed 文献 · J Am Acad Dermatol · 2022-11-09

这项随机2b期试验纳入364例活动性非节段性白癜风患者,评估口服JAK3/TEC抑制剂利特昔替尼的疗效与安全性。24周剂量探索期内,50 mg组(含或不含负荷剂量)及30 mg组在面部白癜风面积评分指数较基线的百分比变化上均显著优于安慰剂。48周治疗期间未见治疗中出现的不良事件或严重不良事件呈剂量依赖性趋势。

要点

  • 利特昔替尼50 mg含负荷剂量组面部白癜风面积评分指数较基线变化-21.2,安慰剂组2.1(P < .001)。
  • 利特昔替尼50 mg不含负荷剂量组变化-18.5,安慰剂组2.1(P < .001)。
  • 利特昔替尼30 mg组变化-14.6,安慰剂组2.1(P = .01)。

核心结论

  • 口服利特昔替尼在活动性非节段性白癜风患者中治疗48周有效且耐受性良好。

研究设计与样本

  • 随机2b期临床试验(NCT03715829),患者随机接受每日一次口服利特昔替尼(200/50 mg、100/50 mg、30 mg或10 mg,含或不含4周负荷剂量)或安慰剂治疗24周(剂量探索期),随后在24周扩展期接受利特昔替尼200/50 mg每日一次。
  • 剂量探索期共治疗364例患者;扩展期接受利特昔替尼200/50 mg治疗的患者为187例。

主要发现

  • 第24周面部白癜风面积评分指数较基线百分比变化:利特昔替尼50 mg含负荷剂量组-21.2 vs 安慰剂组2.1(P < .001)。
  • 第24周面部白癜风面积评分指数较基线百分比变化:利特昔替尼50 mg不含负荷剂量组-18.5 vs 安慰剂组2.1(P < .001)。
  • 第24周面部白癜风面积评分指数较基线百分比变化:利特昔替尼30 mg组-14.6 vs 安慰剂组2.1(P = .01)。
  • 扩展期接受利特昔替尼200/50 mg治疗后观察到改善加速(n = 187)。
  • 48周治疗期间未观察到治疗中出现的不良事件或严重不良事件呈剂量依赖性趋势。

关键数值与推荐

  • 主要疗效终点为第24周面部白癜风面积评分指数较基线的百分比变化。
  • 利特昔替尼50 mg含负荷剂量组第24周面部白癜风面积评分指数较基线变化-21.2,安慰剂组2.1(P < .001)。
  • 利特昔替尼50 mg不含负荷剂量组第24周面部白癜风面积评分指数较基线变化-18.5,安慰剂组2.1(P < .001)。
  • 利特昔替尼30 mg组第24周面部白癜风面积评分指数较基线变化-14.6,安慰剂组2.1(P = .01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仅排除了病情稳定的白癜风患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin. OBJECTIVE: To evaluate the efficacy and safety of ritlecitinib, an oral JAK3 (Janus kinase)/TEC (tyrosine kinase expressed in hepatocelluar carcinoma) inhibitor, in patients with active nonsegmental vitiligo in a phase 2b trial (NCT03715829). METHODS: Patients were randomized to once-daily oral ritlecitinib ± 4-week loading dose (200/50 mg, 100/50 mg, 30 mg, or 10 mg) or placebo for 24 weeks (dose-ranging period). Patients subsequently received ritlecitinib 200/50 mg daily in a 24-week extension period. The primary efficacy endpoint was percent change from baseline in Facial-Vitiligo Area Scoring Index at week 24. RESULTS: A total of 364 patients were treated in the dose-ranging period. Significant differences from placebo in percent change from baseline in Facial-Vitiligo Area Scoring Index were observed for the ritlecitinib 50 mg groups with (-21.2 vs 2.1; P < .001) or without (-18.5 vs 2.1; P < .001) a loading dose and ritlecitinib 30 mg group (-14.6 vs 2.1; P = .01). Accelerated improvement was observed after treatment with ritlecitinib 200/50 mg in the extension period (n = 187). No dose-dependent trends in treatment-emergent or serious adverse events were observed across the 48-week treatment. LIMITATIONS: Patients with stable vitiligo only were excluded. CONCLUSIONS: Oral ritlecitinib was effective and well tolerated over 48 weeks in patients with active nonsegmental vitiligo.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2022. PMID: 36370907. doi:10.1016/j.jaad.2022.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。